Kymera Therapeutics (KYMR) Proxy filing summary

Voting matters and shareholder proposals

• Four class III directors are nominated for election to serve until the 2029 Annual Meeting or until a successor is duly elected and qualified.

• Shareholders are asked to approve, on a non-binding advisory basis, the compensation of named executive officers.

• Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is proposed.

• Additional business may be transacted if properly brought before the meeting or any adjournment.

Board of directors and corporate governance

• Director nominees include Bruce Booth, Nello Mainolfi, John Maraganore, and Elena Ridloff.

• Elected directors will serve until the 2029 Annual Meeting or until a successor is qualified.

Executive compensation and say-on-pay

• Advisory vote is requested on the compensation of named executive officers.